Real-World dupixent study shows promise for eczema sufferers
NCT ID NCT06099704
First seen May 20, 2026 · Last updated May 23, 2026 · Updated 1 time
Summary
This study followed 305 Canadian patients aged 6 and older with moderate-to-severe atopic dermatitis (eczema) who were prescribed Dupixent as part of their routine care. Researchers measured how many patients saw at least a 75% improvement in their eczema symptoms after 6, 12, and 18 months. The goal was to see how well the treatment works in everyday life, not just in a controlled trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE TO SEVERE ATOPIC DERMATITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Investigational Site Number : 1240002
Ajax, Ontario, L1S 7K8, Canada
-
Investigational Site Number : 1240003
Regina, Saskatchewan, S4V 1R9, Canada
-
Investigational Site Number : 1240005
Richmond Hill, Ontario, L4E 4L6, Canada
-
Investigational Site Number : 1240006
Pointe-Claire, Quebec, H9R 5M7, Canada
-
Investigational Site Number : 1240007
Edmonton, Alberta, T5K 1X3, Canada
-
Investigational Site Number : 1240008
Peterborough, Ontario, K9J5K2, Canada
-
Investigational Site Number : 1240009
Edmonton, Alberta, T5J 3S9, Canada
-
Investigational Site Number : 1240010
Surrey, British Columbia, V3R 6A7, Canada
-
Investigational Site Number : 1240011
Etobicoke, Ontario, M8X 1Y9, Canada
-
Investigational Site Number : 1240012
Montreal, Quebec, H3H 2R9, Canada
-
Investigational Site Number : 1240013
Québec, G1W 4R4, Canada
-
Investigational Site Number : 1240014
Toronto, Ontario, M5G 1X8, Canada
-
Investigational Site Number : 1240015
Toronto, Ontario, M5G 1E2, Canada
-
Investigational Site Number : 1240016
London, Ontario, N6A 5R9, Canada
-
Investigational Site Number : 1240017
Montreal, Quebec, H3T 1C5, Canada
-
Investigational Site Number : 1240018
Waterloo, Ontario, N2J 1C4, Canada
-
Investigational Site Number : 1240019
Calgary, Alberta, T2J 7E1, Canada
-
Investigational Site Number : 1240020
Halifax, Nova Scotia, B3H 4R2, Canada
-
Investigational Site Number : 1240021
Calgary, Alberta, T3B 6A8, Canada
-
Investigational Site Number : 1240023
Saint-Jean-sur-Richelieu, Quebec, J3A 1B5, Canada
-
Investigational Site Number : 1240024
Barrie, Ontario, L4M 7G1, Canada
-
Investigational Site Number : 1240025
Newmarket, Ontario, L3Y 5G8, Canada
-
Investigational Site Number : 1240026
Fredericton, New Brunswick, E3B 1G9, Canada
-
Investigational Site Number : 1240027
Saskatoon, Saskatchewan, S7K 2C1, Canada
-
Investigational Site Number : 1240028
Nanaimo, British Columbia, V9V 1A3, Canada
-
Investigational Site Number : 1240029
Winnipeg, Manitoba, R3M 3Z4, Canada
-
Investigational Site Number : 1240030
Toronto, Ontario, M4E 1R7, Canada
-
Investigational Site Number : 1240031
Cobourg, Ontario, K9A 0Z4, Canada
-
Investigational Site Number : 1240033
Toronto, Ontario, M3B 0A7, Canada
-
Investigational Site Number : 1240034
Whitby, Ontario, L1N 8M7, Canada
Conditions
Explore the condition pages connected to this study.